Table 1.

Main clinical and biochemical data of the study population (stages 2–5 CKD)

CharacteristicWhole Group (N=755)GLUT9P Value
GG (n=61)GT+TT (n=694)
Age (yr)62±1161±1162±110.56
Men6054610.33
Smoker5034510.01
Diabetes3531350.51
With cardiovascular comorbidities3126320.36
On antihypertensive treatment9794970.33
On treatment with allopurinol4238430.44
Body mass index (kg/m2)28±527.6±3.828.2±4.70.26
Systolic BP (mmHg)134±18133±16134±180.60
Diastolic BP (mmHg)78±1177±978±110.80
Heart rate (beats/min)72±1071±1272±90.40
Cholesterol (mg/dl)187±45179±49187±440.20
HDL cholesterol (mg/dl)50±1749±1450±170.49
LDL cholesterol (mg/dl)112±42109±47112±420.62
Triglycerides (mg/dl)152±80162±80151±800.33
Hemoglobin (g/dl)12.8±1.812.7±1.613.0±1.80.48
Albumin (g/dl)4.2±0.54.2±0.44.2±0.50.95
Phosphate (mg/dl)3.73±0.783.63±0.863.73±0.770.35
High-sensitivity C-reactive protein (mg/dl)2.4 (1.0–5.5)1.9 (0.7–5.3)2.4 (1.1–5.4)0.19
Uric acid (mg/dl)6.7±1.86.5±1.66.7±1.80.30
GFRMDRD186 (ml/min per 1.73 m2)36±1337±1536±130.39
Urinary protein (mg/24 h)0.6 (0.2–1.5)0.3 (0.1–1.1)0.7 (0.2–1.4)0.01
  • Data are expressed as mean±SD, median (interquartile range), or percent frequency, as appropriate. GFRMDRD186, GFR measured by the Modification of Diet in Renal Disease study formula.